XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 34 filers reported holding XILIO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $950 | -19.4% | 450,000 | 0.0% | 0.04% | +10.8% |
| Q2 2023 | $1,179 | -17.4% | 450,000 | 0.0% | 0.04% | -56.5% |
| Q1 2023 | $1,427 | +17.8% | 450,000 | 0.0% | 0.08% | +25.0% |
| Q4 2022 | $1,211 | -99.9% | 450,000 | 0.0% | 0.07% | +21.4% |
| Q3 2022 | $1,310,000 | -0.3% | 450,000 | 0.0% | 0.06% | -20.0% |
| Q2 2022 | $1,314,000 | -58.7% | 450,000 | 0.0% | 0.07% | -47.4% |
| Q1 2022 | $3,182,000 | -55.8% | 450,000 | 0.0% | 0.13% | -31.8% |
| Q4 2021 | $7,200,000 | – | 450,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $4,569,377 | 5.29% |
| Trustees of Columbia University in the City of New York | 249,635 | $791,343 | 1.42% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $8,747,120 | 1.18% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $8,893 | 1.11% |
| Octagon Capital Advisors LP | 2,425,000 | $7,687,250 | 1.11% |
| HARVARD MANAGEMENT CO INC | 416,059 | $1,323,068 | 0.14% |
| Rock Springs Capital Management LP | 1,440,759 | $4,567,206 | 0.11% |
| Artal Group S.A. | 450,000 | $1,427 | 0.08% |
| Soleus Capital Management, L.P. | 226,941 | $719,403 | 0.07% |
| Cannell Capital | 17,025 | $53,969 | 0.01% |